Core Insights - OPKO Health, Inc. reported a significant decrease in total revenues for Q4 2025, amounting to $148.5 million, down from $183.6 million in Q4 2024, primarily due to the sale of certain BioReference assets [3][11] - The company experienced an operating loss of $38.3 million in Q4 2025 compared to a loss of $33.1 million in the same quarter of 2024 [3][16] - OPKO has entered into a research collaboration with Regeneron Pharmaceuticals, which could yield potential milestone payments exceeding $200 million for each program, with an overall potential value exceeding $1 billion [1][2] Business Highlights - A research collaboration with Regeneron Pharmaceuticals aims to develop multispecific antibodies using ModeX's MSTAR technology platform [1] - Merck completed a Phase 1 trial for an Epstein-Barr virus vaccine, with further studies planned [1] - MDX2003, a trispecific T-cell engager for leukemia and lymphoma, received approval for Phase 1 studies in Australia [1] - The partnership with Entera Bio has been expanded to advance a first-in-class oral long-acting PTH tablet for hypoparathyroidism [1][2] Financial Performance - Revenue from products in Q4 2025 was $43.7 million, an increase from $37.4 million in Q4 2024, driven by higher sales volumes in international operations [3][11] - Diagnostics revenue for Q4 2025 was $71.1 million, down from $103.1 million in the prior year, mainly due to the sale of BioReference assets [3][11] - Total costs and expenses increased to $88.0 million in Q4 2025 from $82.6 million in Q4 2024, attributed to higher research and development expenses and increased headcount [3][11] 2026 Financial Guidance - For Q1 2026, OPKO projects total revenues between $125 million and $140 million, with full-year revenues expected to range from $530 million to $560 million [4] - The company anticipates total costs and expenses for 2026 to be between $725 million and $750 million [4]

Financial Data and Key Metrics Changes - OPKO Health reported Q3 2025 revenue of $95.2 million, down from $121.3 million in Q3 2024, primarily due to the sale of oncology assets to LabCorp [22] - Total costs and expenses decreased to $115.2 million from $184.2 million year-over-year, including $25.2 million related to sold oncology assets [22] - Diagnostic operating income improved to $81.6 million compared to $58.5 million in Q3 2024 [23] - Consolidated operating income rose to $48.1 million from $14.2 million in 2024, with net income of $21.6 million, or $0.03 per share, compared to $24.9 million in Q3 2024 [25] Business Line Data and Key Metrics Changes - BioReference Health's testing volume increased by approximately 5.3% in Q3 2025 compared to the previous year, excluding sold assets [10] - The 4Kscore test volume increased more than 20% in Q3 2025 versus the comparable year-ago period, driven by a recent FDA label expansion [11] - Pharmaceutical revenue was $56.4 million, an 8% increase from $52.4 million in Q3 2024, with product revenue slightly down to $37.7 million [24] Market Data and Key Metrics Changes - International operations provided steady sales growth and meaningful cash flow, despite foreign currency pressures [18] - Viality contributed $7.5 million in Q3 2025, a 29% increase from the previous year, reflecting lower government rebates [24] Company Strategy and Development Direction - The company completed the sale of BioReference Health's oncology division for $192.5 million, focusing on core clinical testing operations and the 4Kscore test [4] - OPKO Health is advancing its pipeline with four candidates in clinical trials and several in pre-IND stages, including collaborations with Regeneron and Merck [5][12] - The company aims to maximize shareholder value through strategic actions, including share repurchase programs and advancing clinical trials [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic direction and ability to deliver on milestones, with expectations for BioReference Health to achieve profitability and growth [19] - The company anticipates total revenue for Q4 2025 to be between $135 million to $140 million, with a focus on improving operating efficiency [26] Other Important Information - The company has $428 million in cash and equivalents, allowing for ongoing operations and development plans [20] - OPKO Health has repurchased nearly 25 million shares for approximately $33.5 million in 2025, with $126 million remaining under the buyback program [20] Q&A Session Summary Question: How many patients have been dosed at the fifth dose level for MDX2001, and will the program proceed to dose level six? - The company has dosed five patients at the fifth dose level and expects to proceed to the next level after the observation period [30][32] Question: Is the growth of the 4Kscore test related to the recent label expansion? - The growth is primarily based on the former label, but the new label is expected to expand the market significantly [34][35] Question: Can you provide more details on the Regeneron collaboration? - The collaboration includes four specific programs across metabolism, oncology, and immunology, with potential for expansion [40][41] Question: What is the expected gross margin for the diagnostic services business? - The gross margin is expected to be in the mid-20% range for Q4, improving to the high 20% to low 30% range in the first half of next year [49] Question: What is the rationale for targeting both CD19 and CD20 in the new product? - Targeting both antigens aims to prevent or delay the emergence of resistant variants, enhancing treatment efficacy [66][70]